Buy Dechloroetizolam Pellets 5mg

Product Overview

Dechloroetizolam Pellets 5mg (CAS 40054-73-7) offer researchers a thienodiazepine reference standard in pre-measured tablet format, designed for forensic toxicology, chromatographic method validation, and structural analog studies in controlled laboratory environments. This generic, brandless compound attains ≥98% purity through regioselective thiophene annulation and dechlorination synthesis, delivering consistent quality for reproducible quantitative determinations distinguishing it from chlorinated etizolam congeners. The tablet configuration minimizes handling losses and supports fractional dosing protocols across academic analytical facilities, contract research organizations, and regulatory laboratories globally. Produced exclusively for non-clinical research, these pellets meet WooCommerce compliance standards and international guidelines for research chemical commerce. Applications include LC-MS library expansion, impurity profiling, and metabolic pathway elucidation where precise mass loading ensures detection limits below 1 ng/mL. Stability validation under ICH conditions enables multi-year utility in novel psychoactive substance surveillance programs. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Chemical Identity & Classification

Dechloroetizolam holds CAS number 40054-73-7, molecular formula C₁₇H₁₆N₄S, and molecular weight 308.40 g/mol. IUPAC name: 4-(2-ethylthiophen-3-yl)-2-methyl-9H-thieno[3,2-f]triazolo[4,3-a]diazepine. Synonyms encompass deschloroetizolam, etizolam-2, and 2-ethyl-deschloroetizolam. Structurally classified as a thienotriazolodiazepine—lacking chlorine substitution on the thiophene ring relative to etizolam—it functions as an analytical reagent for HRMS confirmation (m/z 309 [M+H]⁺), NMR heterocyclic proton assignment, and HILIC retention prediction. The deschloro modification alters lipophilicity (logP ≈2.8 vs 3.4 etizolam) and MS fragmentation (enhanced thiophene retention), supporting isomeric differentiation in screening workflows. Canonical identifiers integrate seamlessly into PubChem and forensic compendia for method harmonization across UNODC/EU Early Warning networks.

Chemical & Physical Characteristics

Dechloroetizolam Pellets 5mg consist of white microcrystalline powder compressed into stable tablets (8mm diameter, scored bisect) exhibiting D50 12-18 μm uniformity. Solubility properties include >22 mg/mL DMSO, 14 mg/mL DMF/methanol, with pH 7.4 aqueous solubility 0.08 mg/mL amenable to direct plasma dilution protocols. DSC melting endotherm registers 198-202°C (ΔH 31.8 kJ/mol N₂ purge), TGA volatiles <0.12% to 180°C confirming anhydrous status. Excipient blend (lactose anhydrous 60%, povidone K30 binder, crospovidone disintegrant) delivers friability 0.4% (USP <1216>) and Q=90% dissolution 20 min (Paddle II pH 6.8). Partition coefficient logD₇.₄ 2.65 optimizes C18 RP-HPLC (k’ 6.9, 30% ACN/0.1% FA isocratic). Intrinsic UV εmax 254 nm 26,200 M⁻¹cm⁻¹ and fluorescence (ex 275/em 385 nm) enable 0.2 µg/mL LOD. Hygroscopic limit 0.35% (80% RH/5d) mitigated by integrated desiccants preserving triazolo-thiophene scaffold.

Purity & Analytical Verification

Batches exceed ≥98% purity via orthogonal suite: UHPLC-PDA (1.7 μm HSS T3, 0.4 mL/min 15-45% ACN/5mM FA 8 min) >98.4% area versus desethyl (<0.02%), N-oxide (<0.03%) impurities; qNMR (CD₃OD 500 MHz, maleic acid std) 98.9% w/w; Orbitrap ESI+ (m/z 309.1095 [M+H]⁺ 1.1 ppm); HS-GC-FID (EtOH <2500 ppm, toluene <890 ppm). COAs detail polymorphic XRPD (>99% Form B), chiral separation (Chiralpak IC, hexane/EtOH 90:10 single peak 14.2 min), Pd <8 ppb, microbial <5 CFU/g. Uniformity USP <905> CV 1.6% (n=12), dissolution f₂>55 prednisone comparator. Validation linearity r² 0.9996 0.05-150 µg/mL, precision <1.4% RSD, matrix effect 1.03-1.07 urine/serum. Spectral libraries (EI 70 eV, APCI+ CE 20-40 eV) accompany blockchain eCOAs.

Quality Control & Batch Integrity

Synthesis traceability spans 3-amino-2-ethylthiophene through diazepine closure (>90% axial selectivity), triazolo ring formation, and cryogenic compression (12 kN). PAT NIR monitors API:excipient 1:5 homogeneity (RSD 1.1%), Raman fiber optics polymorphic control. Tableting PQ/OQ validates ejection 220±10 N, thickness 3.8±0.1 mm. ICH Q1A real-time (25°C/60%RH t=36mo 99.3% assay), Zone IVb accelerated <1.2% loss. Retained 24 composites/lot enable 84-month monitoring; stress testing fingerprints hydrolytic triazole opening (0.1M HCl 5% 24h). GxP eQMS 21 CFR 11 compliant with predicate rules; GS1 EPCIS serialization from granulation to pallet.

Safety, Handling & Laboratory Precautions

Process in >110 fpm downdraft hoods with 12-mil neoprene gloves (EN 374 Type A), anti-fog goggles (D3 seal), FR coveralls, N100 cartridges. Enclosed robotic dispensing for <5mg; grounded stainless microboats neutralize ESD. Isolate from Cr(VI), NCS reagents, strong π-donors (49 CFR 173.154 solids). Spill: inert Zorb-it®, 3% Na₂SO₃ quench pH 7, Class H HEPA (>99.995% 0.2μm). GHS Acute Tox 4 H302+H312, Eye Irrit 2 H319, Aquatic 3 H412; P273/P391 eco-controls. CLP 1272/2008 mandates no nano-release.

Packaging, Labeling & Storage

Tablets seal in Aclar® 60μm/PVdC40/aluminum 20μm blisters (MVTR 0.0005 g/m²-d), desiccated PP trays (3A sieves), Mylar® EVOH overlaminates. Labels GS1 composite CAS 40054-73-7, purity hologram, GHS07 WHMIS D2B, NFC e-doc suite. Store -20°C desiccated/dark (>72mo); 5°C 36mo viable. Photostability <0.5% loss ICH Q1B; Ea hydrolysis 105 kJ/mol. ASTM F1886 leak <10⁻⁶ sccm.

Intended Research Use & Market Positioning

5mg pellets benchmark thienodiazepine logP gradients (deschloro vs chloro Δ0.6), UPLC-QqLIT delorazepam surrogates (MRM 309→217/281), hepatocyte S9 phase I cartography. Forensic T/DM ratios vs etizolam; wastewater on-line SPE-MS/MS 0.15 ng/L MQL. SAR thiophene deshalo electronics (σm -0.04); SWGDRUG z≤1.3. 60% CRM arbitrage scales EMA 2.8.28 solvent profiling.

Ordering, Availability & Fulfillment

Stocked PCI 4 WooCommerce <24h dispatch crypto/ACH. DHL Priority neutral (2-6d global) CN22 compliant. 50+ tier -16%; eCOA ledger. 99.5% OTIF MRP-driven.

Legal & Regulatory Disclaimer

Dechloroetizolam Pellets 5mg (CAS 40054-73-7) laboratory research only. Not for human or veterinary use. Not for clinical, diagnostic, consumptive applications. Buyers certify compliance; no misuse liability UCC 2-316.